print this page 
text size
Implications of Resistance
A study underscored the importance of achieving CCyR in 12 months for patients with early chronic phase CML
Failure to achieve at least a partial cytogenetic response by 12 months is a key prognostic factor. When failure occurs, the probability of obtaining a complete cytogenetic response at 2 years is <20%.
7
Patients who had achieved CCyR at 12 months had better OS and also better PFS than those who had not (96% vs 74%, respectively).
OS=Overall survival; PFS=Progression-free survival.
Level of Molecular Response was also found to be an important dynamic factor of prognosis.7
- Major Molecular Response at 12 months is indicative of better event-free survival and progression-free survival (PFS)
- Transcript levels after 1-2 months of treatment predicts a late response
- Low levels of residual disease are associated with continuous remission
When failure or suboptimal response occurs, a different approach to treatment is recommended.4,7
Disclaimer: This is an international Web site for SPRYCEL® (dasatinib) and is intended for healthcare professionals outside the U.S.
If you are a U.S. resident, please visit www.SPRYCEL.com.
If you are not a healthcare professional, please visit www.BMS.com.
The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located or practice.